Kaplan-Meier curves. (A) PFS in patients receiving frontline HD-MTX–containing regimens vs patients receiving other systemic treatments: median PFS, 14.2 months; 95% CI, 9.2-NR vs median PFS, 20.8 months; 95% CI, 6.2-NR (P = .68). (B) OS in patients receiving frontline HD-MTX–containing regimens vs patients receiving other systemic treatments: median OS, 93.2 months; 95% CI, 17.0-NR vs median OS, 63.8 months; 95% CI, 21.3-NR (P = .83).